| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc. (REGN) has 19 insiders with recent SEC Form 4 filings, including 0 buys and 64 sells. REGN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Pres | 310.5K | $189.36M | - | |
| CEO | 214.5K | $130.85M | - | |
| VP | 47.8K | $29.18M | - | |
| VP | 29.5K | $18.00M | - | |
| VP | 21.7K | $13.22M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 14, 2024 | Murphy Andrew J54 | EVP Research | Sale+OE | 5,783 | $956.47 | $5,531,289.51 | -0.8% | +7.2% | -30.5% | |
| Mar 1, 2024 | McCourt Marion55 | EVP Commercial | Sell | 358 | $967.50 | $346,365.00 | -2.6% | -1.3% | -28.9% | |
| Mar 1, 2024 | Ryan Arthur F54 | Director | Sell | 100 | $982.05 | $98,205.40 | - | -1.3% | -28.9% | |
| Feb 26, 2024 | Sing George L56 | Director | Sale+OE | 1,000 | $992.50 | $992,500.00 | -1.9% | -1.6% | -26.9% | |
| Feb 26, 2024 | Larosa Joseph J66 | EVP General Counsel And Secret | Sell | 1,000 | $990.00 | $990,000.00 | -2.7% | -1.6% | -26.9% | |
| Feb 26, 2024 | Bassler Bonnie L59 | Director | Sale+OE | 854 | $979.25 | $836,279.50 | -38.2% | -1.6% | -26.9% | |
| Feb 23, 2024 | Sing George L56 | Director | Sale+OE | 3,500 | $967.86 | $3,387,500.00 | -3.2% | -0.1% | -28.6% | |
| Feb 22, 2024 | Larosa Joseph J66 | EVP General Counsel And Secret | Sell | 1,000 | $967.65 | $967,650.00 | -2.6% | +2.0% | -27.4% | |
| Feb 14, 2024 | Van Plew Daniel P | EVP &General Mgr, Industrial | Sell | 10,434 | $942.28 | $9,831,726.98 | -3.3% | +3.9% | -28.9% | |
| Feb 9, 2024 | Fenimore Christopher R.66 | SVP Finance &CFO | Sell | 4,919 | $953.31 | $4,689,319.75 | -4.7% | +1.5% | -25.5% |